anaphylaxis

过敏反应
  • 文章类型: Case Reports
    运动诱发的过敏反应(EIA)是一种罕见且可能危及生命的综合征,其特征是运动引起的过敏反应。尽管阴道分娩伴分娩疼痛对女性来说是一种身体压力,也可能是EIA的触发因素,对于EIA患者的分娩管理策略尚无共识.一名28岁的primigravida因为环境影响评估史被转诊到我们医院,与瘙痒有关,荨麻疹,呼吸窘迫,在身体活动期间加剧。为了避免身体压力,我们选择了硬膜外麻醉的定时引产,并给予预防性静脉内氢化可的松。她在分娩期间阴道分娩,没有症状提示EIA。由于EIA患者很可能在阴道分娩过程中出现过敏反应并伴有分娩疼痛,硬膜外麻醉和预防性类固醇给药可能是EIA孕妇分娩的最合理方法。
    Exercise induced anaphylaxis (EIA) is a rare and potentially life-threatening syndrome characterized by anaphylaxis provoked by exercise. Although vaginal delivery with labor pain is a physical strain for women and a possible trigger for EIA, no consensus exists on the management strategy of delivery in patients with EIA. A 28-year-old primigravida was referred to our hospital because of history of EIA, associated with pruritus, urticaria, and respiratory distress, exacerbated during physical activity. To avoid physical stress, we chose scheduled labor induction with epidural anesthesia, and administered prophylactic intravenous hydrocortisone. She delivered vaginally with no symptoms suggestive of EIA during labor. Since it is quite possible for patients with EIA to develop anaphylaxis during vaginal delivery with labor pain, epidural anesthesia and prophylactic steroid administration may be the most rational approaches for delivery in pregnant women with EIA.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景和目的:雷马唑仑,一种新型苯二氮卓类药物,由于起效快,作用时间短,因此用于手术镇静和全身麻醉。然而,瑞米唑仑致过敏反应(RIA)是一种罕见但严重的并发症.本研究旨在分析RIA的特点,专注于心血管崩溃,并提供安全使用瑞米唑仑的指南。方法:本研究使用2020年系统评价和荟萃分析指南的首选报告项目进行了系统评价。2023年5月26日从PubMed检索的研究文章,使用关键词“雷米咪唑安定和过敏反应”进行了评估,其纳入标准是用英语写的,并与世界过敏组织的过敏反应标准保持一致。而不符合这些标准的研究被排除.截至搜索日期的所有已发表的文章都包括在内,没有任何日期限制。这篇综述分析了年龄等因素,性别,麻醉类型,瑞咪唑安定剂量(推注/连续),过敏症状和体征,使用肾上腺素,血清类胰蛋白酶水平,还有皮肤点刺试验.结果:11例患者中,平均年龄为55.6±19.6岁,男性占81.8%。低血压(81.8%)是最常见的症状,其次是心动过缓(54.5%)和去饱和(36.4%)。两名患者出现心脏骤停。10例患者血清类胰蛋白酶水平证实有过敏反应。肾上腺素是主要的治疗方法,静脉内剂量为0.1mg至0.3mg。结论:当瑞马唑仑给药时,警惕是至关重要的,坚持推荐剂量,并及时用肾上腺素治疗RIA。需要进一步研究以了解风险因素并完善管理策略。提出了安全使用雷米唑仑的指南。
    Background and Objectives: Remimazolam, a novel benzodiazepine, is used for procedural sedation and general anesthesia due to its rapid onset and short duration of action. However, remimazolam-induced anaphylaxis (RIA) is a rare but severe complication. This study aimed to analyze RIA characteristics, focusing on cardiovascular collapse, and provide guidelines for safe remimazolam use. Methods: This study conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Research articles retrieved from PubMed on 26 May 2023, using the keywords \'remimazolam AND anaphylaxis\' were evaluated based on the inclusion criteria of being written in English and aligning with the World Allergy Organization criteria for anaphylaxis, while studies not meeting these criteria were excluded. All published articles up to the search date were included without any date restrictions. The review analyzed factors such as age, sex, type of anesthesia, remimazolam dose (bolus/continuous), allergic symptoms and sign, epinephrine use, serum tryptase levels, and skin prick tests. Results: Among eleven cases, the mean age was 55.6 ± 19.6 years, with 81.8% male. Hypotension (81.8%) was the most common symptom, followed by bradycardia (54.5%) and desaturation (36.4%). Two patients experienced cardiac arrest. Serum tryptase levels confirmed anaphylaxis in ten cases. Epinephrine was the primary treatment, with intravenous doses ranging from 0.1 mg to 0.3 mg. Conclusions: Vigilance is crucial when administering remimazolam, adhering to recommended dosages, and promptly treating RIA with epinephrine. Further research is needed to understand the risk factors and refine the management strategies. Guidelines for safe remimazolam use are proposed.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    大麻过敏是20世纪70年代描述的一种相对较新的现象。在过去的几年中,由于大麻产品的治疗和娱乐用途的增加,观察到其频率增加。可能导致过敏症状的敏化不仅可以通过吸食大麻而发生,而且通过摄入,花粉的吸入,或直接接触。症状的严重程度从良性瘙痒到过敏反应不等。在整个治疗过程中,很少有信息可用于支持临床医生,从诊断开始到治疗结束。在这次审查中,我们介绍了6例患者,这些患者的分子体外检测显示对大麻提取物和/或大麻来源的nsLTP分子致敏(Cans3).基于这些案例,我们就这个话题提出了重要的问题。本文讨论了当前的建议,并强调了不仅对大麻过敏而且对大麻过敏原无症状致敏的进一步研究的重要性,这可以在一定比例的人口中确定。
    Cannabis allergy is a relatively new phenomenon described in the 1970s. Its increased frequency has been observed over the last years due to the increasing therapeutic and recreational use of cannabis-based products. Sensitization possibly leading to allergy symptoms can occur not only through the smoking of cannabis, but also through ingestion, the inhalation of pollen, or direct contact. The severity of symptoms varies from benign pruritus to anaphylaxis. There is scant information available to support clinicians throughout the entire therapeutic process, starting from diagnosis and ending in treatment. In this review, we present six cases of patients in whom molecular in vitro testing revealed sensitization to cannabis extract and/or cannabis-derived nsLTP molecules (Can s 3). Based on these cases, we raise important questions regarding this topic. The article discusses current proposals and highlights the importance of further research not only on cannabis allergy but also on asymptomatic sensitization to cannabis allergens, which may be ascertained in some percentage of the population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    近几十年来,食物过敏显著增加,贝类是全球食物过敏和过敏反应的主要原因,影响儿童和成人。贝类过敏的患病率估计约为普通人群的0.5-2.5%,地理位置差异很大,年龄,和消费习惯。尽管软体动物的消费量有所上升,软体动物过敏的患病率仍然未知。虽然广泛的研究集中在甲壳类动物过敏上,软体动物过敏,特别是那些与腹足类有关的,受到的关注相对较少。贝类过敏的临床表现范围从局部症状到危及生命的全身反应,如过敏反应。值得注意的是,在涉及腹足类的病例中,严重的支气管痉挛是主要的临床特征。已经在软体动物中发现了几种过敏原,包括副肌球蛋白,原肌球蛋白,和肌浆钙结合蛋白。在腹足类动物中,有记载的过敏原包括原肌球蛋白,副肌球蛋白,肌球蛋白的重链,和Derp4淀粉酶。诊断通常涉及全面的临床病史,皮肤测试,免疫球蛋白(Ig)E的体外定量,并通过口头挑战确认,尽管后者是为选定的病例保留的。这篇叙述性综述强调了对腹足动物过敏的有限研究。它提供了纯化和重组过敏原的全面列表,并讨论了成分解析诊断的应用以及当前的治疗进展。
    Food allergies have increased significantly in recent decades, with shellfish being a leading cause of food allergy and anaphylaxis worldwide, affecting both children and adults. The prevalence of shellfish allergies is estimated to be approximately 0.5-2.5% of the general population, varying significantly by geographical location, age, and consumption habits. Although mollusk consumption has risen, the prevalence of mollusk allergies remains unknown. While extensive research has focused on crustacean allergies, mollusk allergies, particularly those related to gastropods, have received comparatively less attention. Clinical manifestations of shellfish allergy range from localized symptoms to life-threatening systemic reactions, such as anaphylaxis. Notably, severe bronchospasm is a predominant clinical feature in cases involving gastropods. Several allergens have been identified in mollusks, including paramyosin, tropomyosin, and sarcoplasmic calcium-binding protein. In gastropods, documented allergens include tropomyosin, paramyosin, the heavy chain of myosin, and Der p 4 amylase. Diagnosis typically involves a thorough clinical history, skin testing, in vitro quantification of immunoglobulin (Ig) E, and confirmation through an oral challenge, although the latter is reserved for selected cases. This narrative review highlights the limited research on gastropod allergy. It provides a comprehensive list of purified and recombinant allergens and discusses the applications of component-resolved diagnosis as well as current therapeutic developments.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景。食物过敏可以从轻度到重度,具有各种症状和器官受累的危及生命的反应。哮喘对严重食物引起的过敏反应的影响尚不完全清楚。假设哮喘会增加严重食物引起的过敏反应的风险,本研究的目的是比较有哮喘病史的患者与无哮喘病史的患者中严重食物引起的过敏反应的发生率.方法。我们对电子数据库进行了系统的研究,包括PubMed,Scopus,和WebofScience。观察性研究,报告被诊断为食物过敏患者的医学特征的研究,并纳入报告有过敏反应患者病史的研究.主要结果是有哮喘病史的患者与没有哮喘病史的患者相比,严重的食物引起的过敏反应的发生率。本综述的方案在PROSPERO(CRD42023448293)中注册。结果。8项研究共90,367例患者符合纳入标准并被纳入,共有28,166名食物过敏患者。与无哮喘病史的患者相比,有哮喘病史的患者中严重食物引起的过敏反应的发生率增加(OR=1.28;95%CI1.03-1.59;p=0.03;I2=59%)。Conclusions.同时患有食物过敏和哮喘的人患严重的风险很高,可能致命的过敏反应.医疗保健专业人员应优先考虑这些主题的预防和管理策略。
    UNASSIGNED: Background. Food allergy can range from mild to severe, life-threatening reactions with various symptoms and organ involvement. The impact of asthma on severe food-induced allergic reactions is not completely understood. In the hypothesis that asthma increases the risk of severe food-induced allergic reactions, the aim of this study is to compare the incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma. Methods. We performed a systematic research on electronic databases, including PubMed, Scopus, and Web of Science. Observational studies, studies reporting medical characteristics of patients diagnosed with food allergy, and studies reporting medical history of patients with allergic reactions were included. The primary outcome was the incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma. The protocol of this review was registered in PROSPERO (CRD42023448293). Results. Eight studies with a total of 90,367 patients met the inclusion criteria and were included, with a total population of 28,166 of patients with food allergy. The incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma was increased (OR = 1.28; 95% CI 1.03-1.59; p = 0.03; I2 = 59%). Conclusions. Individuals with both food allergy and asthma are at high risk of severe, potentially fatal allergic reactions. Healthcare professionals should prioritize prevention and management strategies for these subjects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:牛奶和鸡蛋过敏影响约1.9%和0.9%的儿童,分别。饮食进步疗法(DAT),包括牛奶(ML)和鸡蛋(EL)梯子,烤牛奶(BM-OIT)和烤鸡蛋(BE-OIT)口服免疫疗法是这些患者的潜在治疗选择。
    目的:对IgE介导的牛奶或鸡蛋过敏儿童DAT的安全性和有效性进行系统评价和荟萃分析。
    方法:进行了系统的文献综述,探索22种潜在结果,进行荟萃分析,其中>3项研究报告数据。等级方法用于确定每个结果的证据的确定性,以及JohannaBriggs研究所用于确定偏差风险的工具。
    结果:在筛选的9946项研究中,有29项研究符合纳入标准。公差发生在69%的EL,58%的ML,49%的BE-OIT和29%的BM-OIT患者。所有严重的过敏反应发生在21%的EL,25%的ML,20%的BE-OIT和61%的BM-OIT患者,在3%的EL中使用肾上腺素,2%的ML,和9%的BM-OIT患者。19%的BE-OIT患者和10%的BM-OIT患者发生家庭反应。停药发生在14%的EL,17%的ML,17%的BE-OIT和20%的BM-OIT患者。产卵和BE-OIT耐受性的平均时间为13.25个月(4项研究)和19.1个月(3项研究)。证据的确定性很低,偏见的风险很高。研究异质性高,可归因于多种因素。
    结论:支持DAT安全性和有效性的证据的确定性非常低。我们不能得出DAT加速耐受性发展的结论。
    BACKGROUND: Cow\'s milk and egg allergy affect approximately 1.9% and 0.9% of children, respectively. Dietary advancement therapies (DAT), including milk (ML) and egg (EL) ladders, baked milk (BM-OIT) and baked egg (BE-OIT) oral immunotherapy are potential therapeutic options for these patients.
    OBJECTIVE: To perform systematic review and meta-analysis of the safety and efficacy of DAT in children with IgE-mediated milk or egg allergy.
    METHODS: A systematic literature review was conducted, exploring 22 potential outcomes, with meta-analysis performed where >3 studies reported data. The GRADE approach was used to determine the certainty of evidence for each outcome, and the Johanna Briggs Institute tools for determining risk of bias.
    RESULTS: Twenty-nine studies met inclusion criteria among 9946 titles screened. Tolerance occurred in 69% of EL, 58% of ML, 49% of BE-OIT and 29% of BM-OIT patients. All-severity allergic reactions occurred in 21% of EL, 25% of ML, 20% of BE-OIT and 61% of BM-OIT patients, with epinephrine use in 3% of EL, 2% of ML, and 9% of BM-OIT patients. At-home reactions occurred in 19% of BE-OIT and 10% of BM-OIT patients. Discontinuation occurred in 14% of EL, 17% of ML, 17% of BE-OIT and 20% of BM-OIT patients. Mean time to BE egg and BE-OIT tolerance was 13.25 months (4 studies) and 19.1 months (3 studies). Certainty of evidence was very low, and risk of bias high. Study heterogeneity was high, attributable to multiple factors.
    CONCLUSIONS: There is very low certainty of evidence supporting DAT safety and efficacy. We cannot conclude DAT accelerates tolerance development.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:聚维酮,一种常用于各种产品如防腐剂的合成聚合物,化妆品,和药物,与过敏反应有关,包括过敏反应.尽管它广泛使用,聚维酮引起的过敏反应,尤其是在儿童中,被低估了。本病例报告旨在强调在出现过敏反应的儿科患者中考虑聚维酮过敏的重要性。病例介绍:我们描述了一个3岁的男孩,在将聚维酮碘消毒液应用于腿部伤口后出现过敏反应。他出现了全身性荨麻疹,血管性水肿,呼吸困难,还有咳嗽.急诊部门已开始及时诊断和管理。在眼科就诊期间,他使用含聚维酮的滴眼液进行了第二次过敏反应。结论:出现过敏反应的儿科患者应考虑聚维酮过敏,特别是那些有特发性反应或多种药物过敏的人。临床医生应强调对患者进行标签阅读和提供肾上腺素自动注射器的教育,以防止与聚维酮接触相关的危及生命的反应。
    Background: Povidone, a synthetic polymer commonly used in various products such as antiseptics, cosmetics, and medications, has been associated with allergic reactions, including anaphylaxis. Despite its widespread use, cases of povidone-induced anaphylaxis, especially in children, are under-recognized. This case report aims to highlight the importance of considering povidone allergy in pediatric patients presenting with anaphylaxis. Case Presentation: We describe a 3-year-old boy who experienced anaphylaxis following the application of povidone-iodine antiseptic solution to a leg wound. He presented with generalized urticaria, angioedema, dyspnea, and cough. Prompt diagnosis and management were initiated in the emergency department. He experienced the second anaphylaxis with povidone-containing eye drops prescribed during an ophthalmology visit. Conclusions: Povidone allergy should be considered in pediatric patients presenting with anaphylaxis, especially those with idiopathic reactions or multiple drug allergies. Clinicians should emphasize patient education on label reading and the provision of adrenaline autoinjectors to prevent life-threatening reactions associated with povidone exposure.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:雷马唑仑是最近开发的,用作全身麻醉药的超短作用苯二氮卓类药物。已经报道了一些瑞米唑仑过敏反应的病例,但是它的特征还没有被完全理解。我们提供了一个有趣的病例报告和文献综述,以更好地了解雷米咪唑仑过敏反应。
    方法:一名拟行机器人辅助胃切除术的75岁男性患者,在全身麻醉诱导过程中给予瑞米唑仑。插管后,观察到低呼气末CO2,高气道压力和并发循环衰竭。支气管镜检查显示明显的气管和支气管水肿,我们诊断为过敏反应。患者在支气管镜检查后心脏骤停,但通过静脉注射肾上腺素和胸部按压立即康复。我们对诱导过程中使用的药物进行了皮肤点刺试验,除了雷米唑仑,考虑到瑞米唑仑全身不良反应的高风险。我们诊断为雷米唑仑过敏反应,因为麻醉期间使用的其他药物的皮肤点刺试验结果为阴性,在随后的手术中,这些药物可以在没有过敏反应的情况下使用。此外,该患者一年前接受心脏手术时经历了严重的过敏性反应,在使用咪达唑仑的时候,但当时人们认为它不是过敏原。基于这些发现,怀疑与瑞马唑仑和咪达唑仑有交叉反应性.然而,该患者先前接受了另一种苯二氮卓类药物,溴替唑仑,他并不过敏,这表明利马唑仑的交叉反应性可能在苯二氮卓类药物之间有所不同。在这篇文章中,我们回顾了文献中描述的11例瑞米唑仑过敏反应。
    结论:雷马唑仑是一种超短作用的镇静剂;然而,会引起危及生命的过敏反应.此外,其与其他苯二氮卓类药物的交叉反应性尚未完全了解。为了增加这种药物的安全性,需要进一步的研究和更多的使用经验。
    BACKGROUND: Remimazolam is a recently developed, ultrashort-acting benzodiazepine that is used as a general anesthetic. Some cases of remimazolam anaphylaxis have been reported, but its characteristics are not fully understood. We present an interesting case report and review of the literature to better understand remimazolam anaphylaxis.
    METHODS: A 75-year-old man scheduled for robot-assisted gastrectomy was administered remimazolam for the induction of general anesthesia. After intubation, low end-expiratory CO2, high airway pressure and concurrent circulatory collapse were observed. Bronchoscopy revealed marked tracheal and bronchial edema, which we diagnosed as anaphylaxis. The patient suffered cardiac arrest after bronchoscopy but recovered immediately with intravenous adrenaline administration and chest compressions. We performed skin prick tests for the drugs used during induction except for remimazolam, considering the high risk of systemic adverse reactions to remimazolam. We diagnosed remimazolam anaphylaxis because the skin prick test results for the other drugs used during anesthesia were negative, and these drugs could have been used without allergic reactions during the subsequent surgery. Furthermore, this patient had experienced severe anaphylactic-like reactions when he underwent cardiac surgery a year earlier, in which midazolam had been used, but it was not thought to be the allergen at that time. Based on these findings, cross-reactivity to remimazolam and midazolam was suspected. However, the patient had previously received another benzodiazepine, brotizolam, to which he was not allergic, suggesting that cross-reactivity of remimazolam may vary among benzodiazepines. In this article, we reviewed the 11 cases of remimazolam anaphylaxis that have been described in the literature.
    CONCLUSIONS: Remimazolam is an ultrashort-acting sedative; however, it can cause life-threatening anaphylaxis. In addition, its cross-reactivity with other benzodiazepines is not fully understood. To increase the safety of this drug, further research and more experience in its use are needed.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    人粒细胞集落刺激因子(G-CSF)是一种用于治疗化疗后中性粒细胞减少症的粒细胞生长因子,清髓性治疗,或准备同种异体移植的健康供体。很少有过敏反应(HRs)的报道,其真正的流行率是未知的。我们旨在系统地表征G-CSF诱导的HR,同时包括全面的不良反应列表。我们通过在PubMed中搜索来审查2024年1月之前发表的文章,Embase,科克伦图书馆,和WebofScience数据库使用列出的关键字的组合,选择了需要的,并提取相关数据。搜索结果有68个条目,与我们的研究相关的17个,以及从手动搜索书目来源中发现的其他7个。总共描述了40例G-CSF诱导的HR,并分为立即(29)或延迟(11)。近期主要是由非格司亭(最少13例)引起的,在WAO过敏反应量表上至少有9人是5级。延迟反应主要是斑丘疹性皮疹,并允许G-CSF继续。首次暴露后的反应经常出现,并且在40例中的至少11例中存在。在分析的数据中,仅发现了五种脱敏方案。我们相信这项研究揭示了该主题的研究兴趣,可以从进一步的探索中受益,并建议定期更新,以包括最近发布的证据。
    Human granulocyte colony-stimulating factor (G-CSF) is a granulopoietic growth factor used in the treatment of neutropenia following chemotherapy, myeloablative treatment, or healthy donors preparing for allogeneic transplantation. Few hypersensitivity reactions (HRs) have been reported, and its true prevalence is unknown. We aimed to systematically characterize G-CSF-induced HRs while including a comprehensive list of adverse reactions. We reviewed articles published before January 2024 by searching in the PubMed, Embase, Cochrane Library, and Web of Science databases using a combination of the keywords listed, selected the ones needed, and extracted relevant data. The search resulted in 68 entries, 17 relevant to our study and 7 others found from manually searching bibliographic sources. A total of 40 cases of G-CSF-induced HR were described and classified as immediate (29) or delayed (11). Immediate ones were mostly caused by filgrastim (13 minimum), with at least 9 being grade 5 on the WAO anaphylaxis scale. Delayed reactions were mostly maculopapular exanthemas and allowed for the continuation of G-CSF. Reactions after first exposure frequently appeared and were present in at least 11 of the 40 cases. Only five desensitization protocols have been found concerning the topic at hand in the analyzed data. We believe this study brings to light the research interest in this topic that could benefit from further exploration, and propose regular updating to include the most recently published evidence.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:红色进口火蚁(RIFA)是世界上最具破坏性的入侵物种之一。RIFA刺痛会导致过敏反应,包括危及生命的过敏反应,然而,健康影响仍未得到充分定义。方法:从开始到2023年9月20日,我们使用与红色进口火蚁和过敏相关的搜索词搜索了MEDLINE(Ovid)和GoogleScholar(灰色文献)的英文文章,包括过敏反应.结果:每年RIFA感染地区约有三分之一的人口被刺痛。最常见的反应是皮肤上的无菌1-2毫米假脓疱。大约20%的刺痛引起大的局部反应,大约0.5%至2%的刺痛引起全身性过敏反应,其范围可以从皮肤症状到危及生命的过敏反应。当地生物多样性也因入侵RIFA而受到严重破坏,并可能对人类健康产生复杂的不利影响,从农业损失到病原体媒介的扩大范围。结论:红色进口火蚁在西太平洋建立自己的入侵物种的潜力带来了巨大而昂贵的健康问题。成功的根除和监测计划,识别和根除新的入侵,将避免重大的健康影响和成本。
    Background: The red imported fire ant (RIFA) is one of the world\'s most destructive invasive species. RIFA stings are painful and can lead to allergic reactions, including life-threatening anaphylaxis, yet health impacts remain inadequately defined. Methods: We searched MEDLINE (Ovid) and Google Scholar (grey literature) from inception until 20 September 2023 for articles in English using search terms related to red imported fire ants and allergies, including anaphylaxis. Results: Approximately a third of the population in RIFA-infested areas are stung each year. The most frequent reaction is a sterile 1-2 mm pseudo pustule on the skin. Approximately 20% of stings cause a large local reaction and between about 0.5% and 2% stings cause a systemic allergic reaction which can range from skin symptoms to life-threatening anaphylaxis. Local biodiversity is also significantly disrupted by invading RIFA and may lead to complex adverse effects on human health, from agriculture losses to expanded ranges for pathogen vectors. Conclusions: The potential for red imported fire ants to establish themselves as an invasive species in the Western Pacific presents a substantial and costly health issue. Successful eradication and surveillance programs, to identify and eradicate new incursions, would avoid substantial health impacts and costs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号